
PEARL Trial: A Blow to Rapamycin’s Healthspan Narrative?
Physionic
Oct 14, 2024
Mindsip insights from this episode:
Confirm safety of low-dose rapamycin in PEARL trial
The PEARL trial was primarily a safety study and concluded that there were no serious adverse effects linked to rapamycin at the tested doses over 48 weeks.
Demand funding for definitive rapamycin clinical trials
A leading expert on rapamycin expressed immense frustration that funders have not stepped up to finance the definitive clinical trials needed to properly evaluate the drug.
Acknowledge limitations of healthy participants in study results
The study's ability to show significant effects was limited because many of the enrolled participants were already quite healthy.
Achieve small gains in bone and muscle with rapamycin
Even with a much lower than intended dose, the 10mg rapamycin group showed small improvements in bone mineral content and muscle mass.
Address dosing flaws in rapamycin trial for accurate results
The recent PEARL trial on rapamycin accidentally used doses that were only about 30% of the intended amount due to a packaging and bioavailability issue.
More from
Physionic
Dave Asprey: Animal Protein is Better, but Don’t eat THIS Animal Protein!
Cheap, Revolutionary Blood Test can Predict your Alzheimer’s Disease Risk
Don’t be Fooled by Coronary Artery Calcium score of 0…
Detox Expert: The Perfect Cleanse to reset your Gut!
The King of Protein, Whey, Finally Defeated by a Newcomer?














